Celltrion, Inc.




Biotechnology & Medical Research

End-of-day quote Korea S.E. 23:00:00 23/05/2024 BST 5-day change 1st Jan Change
179,900 KRW -1.96% Intraday chart for Celltrion, Inc. -6.06% -10.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe CI
Celltrion's Q1 Attributable Profit Slumps 86% MT
Market Share of Celltrion’s Remsima Rises to 74% in Europe MT
Celltrion, Inc. announces an Equity Buyback for 436,047 shares. CI
Celltrion, Inc. authorizes a Buyback Plan. CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024. CI
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million. CI
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US MT
Celltrion's Autoimmune Disease Treatment Hits US Markets MT
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed MT
Celltrion Announces 75 Billion Won Share Buyback Plan MT
Celltrion, Inc. announces an Equity Buyback for 425,895 shares. CI
Celltrion, Inc. authorizes a Buyback Plan. CI
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings MT
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25% MT
Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease CI
South Korean Shares Close Lower on Hotter-Than-Expected US Inflation Data MT
Celltrion Pursues EMA Approval for Actemra Biosimilar MT
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates CI
Celltrion Strikes Key Anti-Cancer Treatment Deals Across Europe MT
Celltrion Holdings Actively Pursuing Nasdaq Listing MT
Celltrion Seeks US Interchangeability Designation for Autoimmune Disease Biosimilar MT
Celltrion Announces Cancellation of Over 1% of Outstanding Shares MT
South Korean Shares Decline After Latest Fed Minutes Indicate Continuation of High-Interest Rates MT
Chart Celltrion, Inc.
More charts
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
179,900 KRW
Average target price
233,647 KRW
Spread / Average Target
  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. News Celltrion, Inc.
  5. Celltrion Pursues EMA Approval for Actemra Biosimilar